There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Blueprint Medicines Corp (BPMC) shows that investor sentiment remained same, with the stock’s consolidated last price to $63.67. The Blueprint Medicines Corp has recorded 93,668 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Blueprint Medicines’ AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $63.67 and fluctuated between $65.56 as its day high and $63.63 as its day low. The current market capitalization of Blueprint Medicines Corp is $3.87B. A total of 0.57 million shares were traded on the day, compared to an average of 613.75K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, BPMC has seen 4 BUY and 8 SELL insider trades, representing the acquisition of 50,000 and the disposition of 54,369 shares. Over the last 12 months, there were 27 BUYs and 35 SELLs from insiders. Insiders purchased 256,475 shares during that period but sold 115,959.
In the most recent transaction, Albers Jeffrey W. sold 1,485 shares of BPMC for 60.13 per share on Nov 03. After the transaction, the Director now owns 176,050 company shares. In a previous transaction on Nov 02, Albers Jeffrey W. sold 4,634 shares at 60.37 per share. BPMC shares that Director owns now total 176,050.
Among the insiders who sold shares, Albers Jeffrey W. disposed of 3,881 shares on Nov 01 at a per-share price of $60.02. This resulted in the Director holding 176,050 shares of BPMC after the transaction. In another insider transaction, Murray Christopher K. sold 600 shares at $56.40 per share on Oct 26. Company shares held by the CHIEF TECHNICAL OPERATIONS now total 25,095.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for BPMC in the last 3 months, the mean price target is $79.00 with high estimates of $114.00 and low estimates of $50.00. In terms of 52-week highs and lows, BPMC has a high of $68.00 and a low of $37.82.
As of this writing, BPMC has an earnings estimate of -$2.04 per share for the current quarter. EPS was calculated based on a consensus of 17 estimates, with a high estimate of -$1.84 per share and a lower estimate of -$2.2. The company reported an EPS of -$2.19 in the last quarter, which was 13.80% higher than expectations of -$2.54.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. BPMC’s latest balance sheet shows that the firm has $1.03B in Cash & Short Term Investments as of fiscal 2021. There were $111.41M in debt and $149.76M in liabilities at the time. Its Book Value Per Share was $3.34, while its Total Shareholder’s Equity was $970.74M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BPMC is Buy with a score of 4.35.